These mechanisms include glutathione (GSH),[8] thioredoxin (Trx, aka TXN),[9] antioxidant enzymes (e.g., glutathione peroxidases (GPXs),[10] catalases (CATs),[11] and superoxide dismutases (SODs),[12] and their transcriptional regulators, such as the nuclear factor erythroid 2‐related factor 2 (Nrf‐2)[13] and BTB domain and CNC homolog 1 (BACH1).[14] Therefore, employing redox‐modulating strategies to specifically target these distinctive biochemical attributes of cancer cells presents a feasible therapeutic approach for cancer treatment. This evidence concerns the gene BACH1 and cancer.